Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX)

Historical Holders from Q3 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
NRIX on Nasdaq
Shares outstanding
77,143,980
Price per share
$18.97
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
84,776,704
Total reported value
$783,330,709
% of total 13F portfolios
0%
Share change
-3,558,953
Value change
-$36,481,022
Number of holders
171
Price from insider filings
$18.97
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.2% $74,655,298 6,284,116 BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 7.2% +35% $65,340,000 +$16,335,000 5,500,000 +33% Deep Track Capital, LP 31 Mar 2025
FMR LLC 4.1% -62% $38,437,849 -$42,758,996 4,159,940 -53% FMR LLC 31 Oct 2025
Commodore Capital LP 4.9% -4% $34,927,708 -$646,292 3,780,055 -1.8% Commodore Capital LP 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 4.2% $37,882,255 3,188,742 Wellington Management Group LLP 31 Mar 2025
As of 30 Sep 2025, Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) has 171 institutional shareholders filing 13F forms. They hold 84,776,704 shares. .

Top 25 institutional shareholders own 92% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 12% 8,887,537 -15% 0% $82,120,843
BlackRock, Inc. 8.8% 6,762,586 -0.68% 0% $62,486,295
Deep Track Capital, LP 7.9% 6,057,024 -0.13% 1.6% $55,966,902
VANGUARD GROUP INC 5.8% 4,488,776 +0.52% 0% $41,476,290
BAKER BROS. ADVISORS LP 5% 3,882,125 0% 0.26% $35,870,835
Commodore Capital LP 4.9% 3,780,055 -4.3% 1.7% $34,927,708
Redmile Group, LLC 4.8% 3,678,394 -1.5% 3.3% $33,988,361
Vestal Point Capital, LP 4.5% 3,475,000 +74% 1.5% $32,109,000
Point72 Asset Management, L.P. 3.7% 2,871,497 -22% 0.06% $26,532,636
STATE STREET CORP 3.7% 2,862,387 +13% 0% $26,448,456
Soleus Capital Management, L.P. 3.1% 2,422,833 0% 1.2% $22,386,977
MORGAN STANLEY 2.9% 2,260,746 +4.3% 0% $20,889,301
Kynam Capital Management, LP 2.8% 2,168,605 +85% 1.5% $20,037,910
Pictet Asset Management Holding SA 2.6% 1,980,540 -0.91% 0.02% $18,300,190
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,882,682 +0.04% 0% $17,397,440
Sumitomo Mitsui Trust Group, Inc. 2% 1,557,479 +12% 0.01% $14,391,106
Amova Asset Management Americas, Inc. 2% 1,557,479 +12% 0.14% $14,391,106
MILLENNIUM MANAGEMENT LLC 2% 1,523,959 +64% 0.01% $14,081,381
ARK Investment Management LLC 2% 1,510,404 -4.1% 0.08% $13,956,133
DEUTSCHE BANK AG\ 1.9% 1,438,859 +290% 0% $13,295,057
PERCEPTIVE ADVISORS LLC 1.8% 1,416,149 +29% 0.38% $13,085,217
T. Rowe Price Investment Management, Inc. 1.6% 1,197,415 -52% 0.01% $11,065,000
PRICE T ROWE ASSOCIATES INC /MD/ 1.4% 1,099,093 -64% 0% $10,156,000
Affinity Asset Advisors, LLC 1.3% 967,620 0% 0.83% $8,940,809
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 864,380 +42% 0% $7,986,871

Institutional Holders of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 31,528 $597,870 +$167,916 $18.97 3
2025 Q3 84,776,704 $783,330,709 -$36,481,022 $9.24 171
2025 Q2 88,319,903 $1,005,945,844 +$40,933,248 $11.39 162
2025 Q1 84,604,516 $1,005,121,870 +$28,666,957 $11.88 168
2024 Q4 81,104,525 $1,528,052,925 +$231,683,434 $18.84 173
2024 Q3 67,558,504 $1,518,295,759 +$52,625,875 $22.47 169
2024 Q2 65,001,644 $1,356,581,082 +$344,064,983 $20.87 172
2024 Q1 48,856,961 $718,184,494 +$58,237,256 $14.70 136
2023 Q4 138,788 $1,432,292 +$214,842 $10.32 3
2023 Q3 44,758,894 $351,805,692 +$8,512,302 $7.86 127
2023 Q2 43,551,266 $434,807,500 +$11,844,588 $9.99 122
2023 Q1 42,320,518 $375,167,257 -$3,615,289 $8.88 118
2022 Q4 42,678,126 $468,600,454 +$2,141,412 $10.98 118
2022 Q3 42,568,400 $554,653,832 -$36,725,357 $13.03 111
2022 Q2 43,489,546 $551,173,048 +$51,851,926 $12.67 96
2022 Q1 40,060,595 $561,209,716 -$19,101,759 $14.01 108
2021 Q4 40,375,553 $1,168,717,078 +$25,729,283 $28.95 117
2021 Q3 38,894,890 $1,166,480,633 -$6,524,537 $29.96 109
2021 Q2 39,077,486 $1,037,035,893 -$75,571,491 $26.53 101
2021 Q1 41,336,305 $1,285,102,277 +$254,605,491 $31.09 98
2020 Q4 33,136,833 $1,089,462,176 +$26,868,072 $32.88 67
2020 Q3 31,854,383 $1,111,189,598 +$1,111,189,708 $34.91 64